First-line endocrine therapy alone could be a reasonable treatment option for hormone-positive, HER2-positive metastatic breast cancer

Julien Peron; O. Tredan; Isabelle Ray-Coquard; Thomas Bachelot; S. I. Labidi Galy; B. Favier; I. Treilleux; J. P. Guastalla

doi:10.1684/bdc.2011.1537

Journal articles

First-line endocrine therapy alone could be a reasonable treatment option for hormone-positive, HER2-positive metastatic breast cancer

Julien Peron ¹ O. Tredan Isabelle Ray-Coquard Thomas Bachelot S. I. Labidi Galy B. Favier I. Treilleux J. P. Guastalla

1 Biostatistiques santé

Département biostatistiques et modélisation pour la santé et l'environnement [LBBE]

Document type :

Journal articles

Domain :

Life Sciences [q-bio]

Complete list of metadata

https://hal-univ-lyon1.archives-ouvertes.fr/hal-02282750
Contributor : Marie-Gabrielle Chautard Connect in order to contact the contributor
Submitted on : Tuesday, September 10, 2019 - 11:23:43 AM
Last modification on : Tuesday, October 18, 2022 - 4:25:41 AM

First-line endocrine therapy alone could be a reasonable treatment option for hormone-positive, HER2-positive metastatic breast cancer

Identifiers

Collections

Citation

Export

Metrics

14

First-line endocrine therapy alone could be a reasonable treatment option for hormone-positive, HER2-positive metastatic breast cancer

Identifiers

Collections

Citation

Export

Share

Metrics

14